Pancreatic ductal adenocarcinoma is most frequently detected at an advanced stage. Such
late detection restricts treatment options and contributes to a dismal 5-year survival rate of 3 …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Background Ovarian cancer continues to have a poor prognosis with the majority of women
diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of …

Background and aim The International Cancer of the Pancreas Screening Consortium met in
2018 to update its consensus recommendations for the management of individuals with …

Mass spectrometry plays a key role in relative quantitative comparisons of proteins in order
to understand their functional role in biological systems upon perturbation. In this review, we …

Markers are needed to facilitate early detection of pancreatic ductal adenocarcinoma
(PDAC), which is often diagnosed too late for effective therapy. Starting with a PDAC cell …

Pancreatic cancer (PC) is often associated with a poor prognosis. Long-standing diabetes
mellitus is considered as an important risk factor for its development. This risk can be …

Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year
survival of< 10% because of diffuse symptoms leading to late-stage diagnosis. That survival …

Over the past decade, chemical labeling with isobaric tandem mass tags, such as isobaric
tags for relative and absolute quantification reagents (iTRAQ) and tandem mass tag (TMT) …

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The
disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in …